NCT03528915 (CRY-NOT) is a clinical trial of Rifamycine treatment in Ophthalmia Neonatorum, sponsored by Centre Hospitalier Universitaire, Amiens.

Who is sponsoring NCT03528915?

NCT03528915 is sponsored by Centre Hospitalier Universitaire, Amiens.

What drugs are being tested in NCT03528915?

Interventions in NCT03528915: Rifamycine treatment, whithout Rifamycine treatment.

What condition does NCT03528915 study?

NCT03528915 studies Ophthalmia Neonatorum.

Is NCT03528915 still recruiting?

NCT03528915 is currently completed. Last updated 23 January 2019.

Last reviewed 2019-01-23 · How we verify

NCT03528915: CRY-NOT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prevalence of Conjunctivitis and Indentification of Risk Factors With and Without Prophylactic Antibiotic Treatment in Neonates

Completed Last updated 23 January 2019

What this trial tests

trial testing Rifamycine treatment in Ophthalmia Neonatorum in 881 participants. Completed in 24 July 2016.

Timeline

9 September 2015

Primary endpoint
12 May 2016

24 July 2016

Quick facts

Lead sponsor	Centre Hospitalier Universitaire, Amiens
Status	Completed
Study type	OBSERVATIONAL
Enrollment	881
Start date	9 September 2015
Primary completion	12 May 2016
Estimated completion	24 July 2016
Sites	1 location across France

Drugs / interventions tested

Rifamycine treatment
whithout Rifamycine treatment

Conditions studied

Ophthalmia Neonatorum — all drugs for Ophthalmia Neonatorum →

Sponsor

Centre Hospitalier Universitaire, Amiens

Who can join

Adults 36 Weeks to 36 Weeks, any sex, with Ophthalmia Neonatorum. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The French guidelines for the use of Rifamycine eye drops in delivery room to prevent neonatal conjunctivitis have been actualized. Only newborns exposed to risk factors of conjunctivitis should be treated, compared to previous guidelines, treating all newborns. currently, there are no data describing risk factors for neonatal conjunctivitis. This study evaluated the incidence of conjunctivitis with or without Rifamycine eye drops treatment in the delivery room. Then risk factors for neonatal conjunctivitis where analyzed.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Centre Hospitalier Universitaire, Amiens trials

Trials by the same sponsor.

NCT07354568 — Prognosis of Patients With Mixed Cardiogenic-Vasoplegic Shock · recruiting
NCT07071662 — Induction of Labor in Breech Presentation · completed
NCT06909487 — Clinical Characterization of Very and Extremely Preterm Infants Who Received Excess Erythrocyte Transfusions With Respec · completed
NCT07037719 — Automatic Detection of Eligible Patients to RAUC Protocol (RAUCISABLE) · recruiting
NCT06996145 — Study of the Isometry of the Anterior Cruciate Ligament From the Center of the Native MRI Insertion Reported on Dynamic · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03528915 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Universitaire, Amiens
Last refreshed: 23 January 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03528915.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing